An interventional study of bowel e-diary in Rectal Cancer and LARS - Low Anterior Resection Syndrome, sponsored by KU Leuven. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-15.
Sponsored by KU Leuven · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Rectal Neoplasms with a site in Belgium — 10 open to participants now, 20 under way, 4 of them phase 3. Rectal Neoplasms · Belgium.
Among the 56 studies in Rectal Neoplasms with a site in Belgium, this one is the 22nd largest by planned enrollment of the 45 interventional ones that give a count, is one of 6 that started in 2024, is one of 13 with no phase, reaches primary completion later than 10 of the 19 other live ones, and was the 49th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →10 of the 56 studies in Rectal Neoplasms with a site in Belgium are open now. Recruiting first, the newest first:
KU Leuven · Sites in Belgium
Ages 18+
Centre Hospitalier Universitaire Saint Pierre · Sites in Belgium
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
University Hospital, Antwerp · Sites in Belgium
Ages 18+
Jules Bordet Institute · Sites in Belgium
Ages 70+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 19
First in 1993; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 158 is above the median of 65 across 1,754 interventional studies indexed under Rectal Neoplasms.
Median enrollment 156 across the 45 interventional studies, 188 across the 7 observational. Of the 34 that completed or were terminated, 5 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 56 have an industry lead sponsor. The 10 most frequent:
KU Leuven is the lead sponsor of 373 studies on the registry; 65 are open to participants now.
KU Leuven has 2 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies in Rectal Neoplasms with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02945566Phase 3University of BirminghamCan we Save the Rectum by Watchful Waiting or TransAnal Surgery Following (Chemo)Radiotherapy Versus Total Mesorectal Excision for Early REctal Cancer? | 2027-08 |
| NCT04503694Jules Bordet InstituteNeoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 56 studies in Rectal Neoplasms with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Colorectal cancer is the 2nd and 3rd most common cancer in respectively women and men, of which about 40% is located in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection, combined with chemoradiotherapy. However, this treatment will negatively impact different aspects of bowel function and the patients' quality of life. These bowel symptoms often remain prevalent, even at 12 months after RC treatment. Most assessment tools are however not capable of capturing the full range or therapeutic-related evolution of these bowel symptoms. Consequently, the aim is to develop a validated bowel diary for diagnosing and evaluation of all bowel symptoms.
In recent years, organ-preserving strategies such as Watch and Wait have become more widely implemented. Although these patients avoid surgical morbidity, emerging evidence shows that neoadjuvant radiotherapy alone can also cause substantial and persistent bowel dysfunction. Therefore, the study population was expanded to include patients managed with a Watch and Wait strategy in addition to those undergoing TME/PME.
Colorectal cancer is the 2nd and 3rd most common cancer in women and men, respectively and represents approximately 13% of all new cancer diagnoses, with 40% of cases specifically situated in the rectum. The gold standard treatment for rectal cancer (RC) is a low anterior resection, combined with chemoradiotherapy. However, given the improved oncological results, functional outcomes, such as bowel symptoms, become more and more important. Approximately 60-90% of RC patients are affected with a wide range of new onset bowel symptoms (incontinence for flatus or feces (solid, liquid), frequent bowel movements, urgency, clustering of defecation and evacuation problems) immediately after rectal treatment. The combination of these specific bowel symptoms and their impact on quality of life (QoL) has been summarized in an international consensus definition and is referred to as the Low Anterior Resection Syndrome (LARS).
Major LARS has an important impact on QoL and has major health economic consequences. This is attributable to its high prevalence after RC treatment, the chronic nature of symptoms and the limited evidence of available therapeutic options. This context leads to repetitive medical consultations, additional technical examinations which are often not very useful and need for prolonged medical treatment (multiple drug regimens), with often limited therapeutic gain. Furthermore, there is a lack of a comprehensive scoring system to identify the different aspects of LARS, leading to inadequate diagnostics and follow-up of symptoms. Based on these considerations, there is a clear need for a comprehensive scoring system for identification of the different aspects of LARS and monitoring of therapeutic treatment.
In recent years, organ-preserving strategies such as Watch and Wait have gained importance in the management of rectal cancer. Although these patients avoid surgical morbidity, growing evidence shows that neoadjuvant radiotherapy alone can also induce substantial and persistent bowel dysfunction, likely due to radiation scatter affecting adjacent pelvic structures. As Watch and Wait is increasingly implemented in clinical practice, it is essential that this patient group is included in the development of a comprehensive scoring system to accurately capture the full spectrum and evolution of bowel symptoms across all treatment pathways.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During this focus group, we aim to achieve various goals: * To gain insight into the bowel symptoms and the consequences patients experienced after treating rectal cancer * To understand the expectations of the patients regarding an electronic bowel diary * To determine whether the questions/items derived from the literature study for the bowel diary are clear and understandable for the patients * To explore other relevant questions/items that should be added to the bowel diary We will include 8-12 patients in this focus group.
In this Delphi survey, a multidisciplinary group of experts and patients will score each item of the long list on a 1-9-point Likert scale from 'Not relevant' (1) to 'Essential' (9) for inclusion in the bowel diary. Finally, a patient consultation meeting and a consensus meeting will be held for the participants who completed the Delphi survey. We will recruit 10-18 Delphi panelists per area of expertise. These panelists are experts with international expert recognition in treating bowel symptoms in the following health care categories (abdominal surgeons, digestive/radiation oncologists, specialized pelvic floor muscle physiotherapists, nursing specialists). In addition, we will include one group comprising 10-18 patients in the Delphi survey, ensuring a comprehensive and holistic perspective on treating bowel symptoms across various healthcare categories.
During this focus group, our objective is to ensure that both the questions and answers are meaningful. We will include 8-12 patients in this focus group.
The participants will be asked to use the newly developed electronic bowel diary for 7 consecutive days. To evaluate the usability of the e-diary, a group of 10 patients will participate in the assessment using the System Usability Scale (SUS). Furthermore we will have conversations with these patients regarding the use of the application: complexity, need for additional support, coherence of the application, user-friendliness, and the need for prior knowledge.
Diagnostic Test: bowel e-diary
To assess the validity of the e-diary (test-retest reliability, construct validity and responsiveness), participants who underwent rectal cancer surgery will complete the e-diary during two distinct 7-day periods.
Diagnostic Test: bowel e-diary
To explore the type and severity of bowel symptoms in patients managed with a Watch and Wait strategy, participants will complete the e-diary during two distinct 7-day periods.
Diagnostic Test: bowel e-diary
This bowel diary will be available on the smartphone in the form of an application.
Selection of items for the newly developed bowel diary
The selection of items for a comprehensive bowel diary in patients with rectal cancer is based on a literature review, a patient focus group and an international Delphi survey. The patient focus group is recorded using an audio and video recording. This recording is transcribed verbatim by the researcher into a Word document. The transcription will be analyzed using NVIVO 9 software. In this Delphi survey, a multidisciplinary group of experts will score each item of the long list on a 1-9-point Likert scale from 'Not relevant' (1) to 'Essential' (9) for inclusion in the bowel diary. Finally, a patient consultation meeting and a consensus meeting will be held for the participants who completed the Delphi survey.
Time frame: 12 months
Assessment of content validity of the newly developed bowel diary in a post-Delphi patient focus group consisting of 8-12 participants
Content validation of the newly developed bowel diary will be tested during interview in the post-Delphi patient focus group. This focus group is recorded using an audio and video recording. This recording are transcribed verbatim by the researcher into a Word document. The transcription will be analyzed using NVIVO 9 software.
Time frame: 12 months
The usability of the newly developed e-diary, assessed with the System Usability Scale (SUS) in patients after rectal surgery for rectal cancer
The participants will be asked to use a newly developed electronic bowel diary for 7 consecutive days. This bowel diary will be available on the smartphone in the form of an application. After 7 days, the usability of this e-diary will be assessed with the System Usability Scale (SUS). The SUS is a questionnaire consisting of 10 items, utilizing a 5-point Likert scale to measure users' perceived satisfaction with the system. It includes two subscales focusing on usability and learnability. Scores on the SUS range from 0 to 100, with no direct correlation to percentiles (i.e., a score of 60 does not signify a usability level of 60%). Instead, a score of 70 points or higher is commonly employed as an initial threshold indicating acceptable usability. This benchmark is derived from the overall mean of more than 200 studies covering various systems and products.
Time frame: 12 months
The usability of the newly developed e-diary will be evaluated through conversations with patients who have undergone rectal surgery for rectal cancer, after these patients have used the e-diary for seven consecutive days
Participants will be instructed to use a newly developed electronic bowel diary via a smartphone app for seven consecutive days. The research will then conduct conversations with the participants covering aspects such as complexity, the need for additional support, application coherence, user-friendliness, pre-existing knowledge requirements, and suggestions for improvement. Audio and video recordings of these conversations will be transferred to the researcher's computer and subsequently transcribed into a Word document. The transcriptions will be analyzed using NVIVO 9 software.
Time frame: 12 months
Construct validity of the newly developed bowel e-diary: Known groups method
Patients will be divided into two groups based on their LARS score: no/minor LARS and major LARS. Over a 7-day period, patients will be asked to complete the bowel diary, which will then be examined to determine if there is a meaningful difference between the two groups. The Mann-Whitney U-test will be used to assess whether the difference is significant, and the C-index will be calculated to evaluate how well the test distinguishes between the groups. A C-index of 0.65 or higher would indicate that the test is effective at differentiating between the groups.
Time frame: 12 months
Construct validity of the newly developed bowel e-diary: Convergent and divergent validity
The bowel diary will be completed by patients over a 7-day period, while the questionnaires (such as LARS, MSKCC-BFI, COREFO, PAC-SYM, QLQ-C30) will be filled out on day 7. The correlation between the bowel diary and the questionnaires (such as LARS, MSKCC-BFI, COREFO, PAC-SYM, QLQ-C30) will be calculated. The correlation will be performed across the entire set of questionnaires and bowel diary items, while pairwise correlations at the subscale level will analyze the relationship between related factors.
Time frame: 12 months
Test-retest reliability of the newly developed bowel e-diary
To investigate the test-retest reliability of the newly developed bowel e-diary, patients will have to fill out the bowel diary application twice, each time for a continuous period of 7 days, during a period when the disorder and treatment do not change (i.e., after the end of adjuvant treatment and/or after closure of an eventual temporary postoperative ileostomy).
Time frame: 12 months
Responsiveness of the newly developed bowel e-diary in patients after rectal surgery for rectal cancer. The newly validated e-diary is the primary outcome.
To evaluate the responsiveness of the new bowel diary, patients will complete the diary for 14 consecutive days. The first 7 days (day 1-7) will be compared with the following 7 days (day 7-14). Internal responsiveness will be calculated using the Standardized Response Mean (SRM) for the bowel diary. External responsiveness will be assessed by calculating the SRM for both the bowel diary and the LARS score and MSKCC-BFI questionnaires.
Time frame: 12 months
Explorative analysis of bowel symptoms in Watch and Wait
To exploratively analyse the type and severity of bowel symptoms in patients managed with a Watch and Wait strategy, and to compare these symptoms with those reported by patients who underwent TME/PME surgery.
Time frame: 12 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2024 (actual). Primary completion is estimated for Jul 2026, 27 months after the start.
Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 27 months is below that.
Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.